Glutaminase (GA) catalyzes the first step in mitochondrial glutaminolysis playing a key role in cancer
metabolic reprogramming. Humans express two types of GA isoforms: GLS and GLS2. GLS isozymes
have been consistently related to cell proliferation, but the role of GLS2 in cancer remains poorly
understood. GLS2 is repressed in many tumor cells and a better understanding of its function in
tumorigenesis may further the development of new therapeutic approaches. We analyzed GLS2
expression in HCC, GBM and neuroblastoma cells, as well as in monkey COS-7 cells. We studied GLS2
expression after induction of differentiation with phorbol ester (PMA) and transduction with the fulllength
cDNA of GLS2. In parallel, we investigated cell cycle progression and levels of p53, p21 and c-Myc
proteins. Using the baculovirus system, human GLS2 protein was overexpressed, purified and analyzed
for posttranslational modifications employing a proteomics LC-MS/MS platform. We have demonstrated
a dual targeting of GLS2 in human cancer cells.